ArticleGMS hygiene and infection control2025
A potential surrogate for poliovirus in testing the efficacy of hand antiseptics according to the Global Poliovirus Containment Action Plan.
Article in GMS hygiene and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As part of the global poliovirus containment program (Global Polio Eradication Initiative, GPEI), European laboratories are increasingly restricted from using the long-established poliovirus type 1 strain LSc-2ab as the reference virus in virucidal efficacy testing of disinfectants.This necessitates the identification of an alternative test virus that closely resembles poliovirus in its chemical resistance, belongs to the picornaviridae family, and is suitable for routine laboratory handling. Materials and methods: In this study, two strains of encephalomyocarditis virus (EMCV) were evaluated as potential substitutes in quantitative suspension tests (according to EN 14476) using five biocidal active substances: ethanol, propan-1-ol, propan-2-ol, glutaral (glutaraldehyde) and peracetic acid. Results: The results demonstrated a strong correlation between the inactivation profiles of EMCV and Sabin poliovirus type 1 vaccine strain LSc-2ab. Due to this close correlation and EMCV's practical advantages in laboratory settings such as availability in a European virus bank, growth in a high titer, it is proposed as a suitable substitution candidate for future virucidal efficacy testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.